Novel insights into the risk-benefit profile of nintedanib in children and adolescents with fibrosing interstitial lung disease (ILD) were provided by late-breaking data presented at the European Respiratory Society (ERS) International Congress 2022 regarding the phase 3 InPedILD clinical trial.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045